Trihexyphenidyl

Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders. Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects. It has largely been replaced by drugs such as levodopa. Trihexyphenidyl was granted FDA approval on 13 May 1949.

Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders. Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects. It has largely been replaced by drugs such as levodopa. Trihexyphenidyl was granted FDA approval on 13 May 1949.

Tihexyphenidyl is indicated as an adjunct in the treatment of parkinsonism, an adjuvant in the treatment of parkinsonism with levodopa, and in the control of extrapyramidal disorders caused by central nervous system drugs.

• Extrapyramidal disorder
• Extrapyramidal symptoms caused by butyrophenones
• Extrapyramidal symptoms caused by dibenzoxazepines
• Extrapyramidal symptoms caused by phenothiazines
• Extrapyramidal symptoms caused by thioxanthenes
• Idiopathic Parkinson's Disease
• Parkinsonism post encephalitic
• Arteriosclerotic Parkinsonism